156 related articles for article (PubMed ID: 29766377)
1. Resolution of femoral metaphyseal dysplasia in CINCA syndrome after long-term treatment with interleukin-1 blockade.
Rigante D; Manna R; Verrecchia E; Marrocco R; Leone A
Clin Rheumatol; 2018 Jul; 37(7):2007-2009. PubMed ID: 29766377
[TBL] [Abstract][Full Text] [Related]
2. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes.
Wittkowski H; Kuemmerle-Deschner JB; Austermann J; Holzinger D; Goldbach-Mansky R; Gramlich K; Lohse P; Jung T; Roth J; Benseler SM; Foell D
Ann Rheum Dis; 2011 Dec; 70(12):2075-2081. PubMed ID: 21908452
[TBL] [Abstract][Full Text] [Related]
3. Neonatal treatment of CINCA syndrome.
Paccaud Y; Berthet G; Von Scheven-Gête A; Vaudaux B; Mivelaz Y; Hofer M; Roth-Kleiner M
Pediatr Rheumatol Online J; 2014; 12():52. PubMed ID: 25584041
[TBL] [Abstract][Full Text] [Related]
4. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy.
Kanariou M; Tantou S; Varela I; Raptaki M; Petropoulou C; Nikas I; Valari M
Pediatrics; 2014 Nov; 134(5):e1468-73. PubMed ID: 25349319
[TBL] [Abstract][Full Text] [Related]
5. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.
Caorsi R; Lepore L; Zulian F; Alessio M; Stabile A; Insalaco A; Finetti M; Battagliese A; Martini G; Bibalo C; Martini A; Gattorno M
Arthritis Res Ther; 2013 Feb; 15(1):R33. PubMed ID: 23442610
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Neven B; Marvillet I; Terrada C; Ferster A; Boddaert N; Couloignier V; Pinto G; Pagnier A; Bodemer C; Bodaghi B; Tardieu M; Prieur AM; Quartier P
Arthritis Rheum; 2010 Jan; 62(1):258-67. PubMed ID: 20039428
[TBL] [Abstract][Full Text] [Related]
7. [Cryopyrin-associated periodic syndromes].
Quartier P; Rodrigues F; Georgin-Lavialle S
Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of CINCA/NOMID Syndrome with Interleukin-1 Blockade.
Macejová Z; Vargová V; Matejka M; Szekanecz Z
Isr Med Assoc J; 2015 Jun; 17(6):389-91. PubMed ID: 26234003
[No Abstract] [Full Text] [Related]
9. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.
Kuemmerle-Deschner JB; Wittkowski H; Tyrrell PN; Koetter I; Lohse P; Ummenhofer K; Reess F; Hansmann S; Koitschev A; Deuter C; Bialkowski A; Foell D; Benseler SM
Arthritis Res Ther; 2013; 15(3):R64. PubMed ID: 23718630
[TBL] [Abstract][Full Text] [Related]
10. CINCA syndrome with surgical intervention for valgus deformity and flexion contracture of the knee joint: A case report.
Harada Y; Fukiage K; Nishikomori R; Suzuki S; Futami T
Mod Rheumatol; 2017 Nov; 27(6):1098-1100. PubMed ID: 25867226
[TBL] [Abstract][Full Text] [Related]
11. Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA).
Rigante D; Leone A; Marrocco R; Laino ME; Stabile A
Rheumatol Int; 2011 Dec; 31(12):1661-4. PubMed ID: 21240490
[TBL] [Abstract][Full Text] [Related]
12. [Significant effect of IL-1 receptor antagonist treatment in two patients who had CINCA syndrome with constant symptoms for 13 years].
Idorn L; Vissing NH; Jensen L; Herlin T
Ugeskr Laeger; 2012 May; 174(22):1537-8. PubMed ID: 22668652
[TBL] [Abstract][Full Text] [Related]
13. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
Lipsker D; Lenormand C
Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
[TBL] [Abstract][Full Text] [Related]
14. Cochlear implantation in a child with CINCA syndrome who also has wide vestibular aqueducts.
Bates JE; Bruce IA; Henderson L; Melling C; Green KM
Cochlear Implants Int; 2012 Aug; 13(3):173-6. PubMed ID: 22333493
[TBL] [Abstract][Full Text] [Related]
15. Switch from anakinra to canakinumab in a severe case of CINCA syndrome.
Rigante D; Verrecchia E; Falsini B; Manna R
Int J Rheum Dis; 2016 Dec; 19(12):1354-1356. PubMed ID: 26585548
[No Abstract] [Full Text] [Related]
16. Post-inflammatory retinal dystrophy in CINCA syndrome.
Rigante D; Stabile A; Minnella A; Avallone L; Ziccardi L; Bersani G; Stifano G; Compagnone A; Falsini B
Rheumatol Int; 2010 Jan; 30(3):389-93. PubMed ID: 19424698
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
[TBL] [Abstract][Full Text] [Related]
18. Delayed reactivation of chronic infantile neurologic, cutaneous, articular syndrome (CINCA) in a patient with somatic mosaicism of CIAS1/NLRP3 gene after withdrawal of anti-IL-1 beta therapy.
Paloni G; Pastore S; Tommasini A; Lepore L; Taddio A
Clin Exp Rheumatol; 2015; 33(5):766. PubMed ID: 26316056
[No Abstract] [Full Text] [Related]
19. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2015; 11(10):1083-92. PubMed ID: 26312542
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
